Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5386 to 5400 of 7710 results

  1. What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy

    Research recommendation
    Published
    26 October 2020

  2. Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis (collected from a range of sources including primary care, imaging and pulmonary rehabilitation results) be combined into a multidimensional analysis that provides accurate and useful information on prognosis?

    Recommendation ID NG115/2 Question Multidimensional assessment of outcomes- How can the individual factors associated with COPD prognosis

    Research recommendation
    Published
    6 February 2019

  3. Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness, cost effectiveness and tolerability of pharmacological monotherapy compared with combination therapy for treating neuropathic pain?

    Recommendation ID CG173/1 Question Monotherapy versus combination therapy for treating neuropathic pain:- What is the clinical effectiveness

    Research recommendation
    Published
    9 June 2015

  4. Is the use of chlorhexidine body wash associated with increased antimicrobial resistance?

    Recommendation ID NG125/2 Question Is the use of chlorhexidine body wash associated with increased antimicrobial resistance? Any

    Research recommendation
    Published
    16 August 2019

  5. There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and personal social services. Some impacts may not have been included in the external assessment group's (EAG) model because of a lack of data (see section 3.12 ), including resource use related to carers (see section 3.13 ). Adopting the technologies may change how care is provided (see section 3.4 ) so their effect on resources is hard to estimate without direct data. So, the committee recommended collecting data on how much using the devices affects resource use, to inform cost-effectiveness estimates. Data on time dedicated to training and spent reviewing device results should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.

    Recommendation ID DG51/01 Question There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and

    Research recommendation
    Published
    7 March 2023

  6. Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost effectiveness of concurrent phlebectomies or foam sclerotherapy for varicose tributaries during truncal endothermal ablation for varicose veins compared with: - truncal endothermal ablation without concurrent phlebectomies or foam sclerotherapy? - truncal endothermal ablation with phlebectomies or foam sclerotherapy, if needed, 6–12 weeks later?

    Recommendation ID CG168/4 Question Truncal treatment with or without concurrent tributary treatment:- What is the clinical and cost effectiveness

    Research recommendation
    Published
    9 June 2015

  7. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary

    Research recommendation
    Published
    6 April 2016

  8. Few women use contraception perfectly (that is, exactly in accordance with the product instructions) and consistently. Pregnancy rates during typical use reflect effectiveness of a method among women who use the method incorrectly or inconsistently. Few data are available on typical use of any contraceptive method among women in the UK. Much of the data on contraceptive effectiveness used in the guideline come from clinical trials or surveys undertaken in other countries such as the USA. Large prospective cohort studies are needed to compare the contraceptive effectiveness of LARC methods with non‑LARC methods during typical use in the UK.

    Recommendation ID CG30/1 Question Few women use contraception perfectly (that is, exactly in accordance with the product instructions)

    Research recommendation
    Published
    25 October 2019

  9. In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced by potential health disbenefits (side effects and risks) as well as non‑contraceptive benefits of LARC (such as alleviation of menorrhagia). Large population studies of appropriate design are needed to determine the effect of these factors on the uptake of LARC methods and the implications for NHS resources.

    Recommendation ID CG30/3 Question In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced

    Research recommendation
    Published
    25 October 2019

  10. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG657/1 Question Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound

    Research recommendation
    Published
    15 November 2019

  11. Use of a simple algorithm compared with a standard clinical assessment:- For people with a common mental health disorder, is the use of a simple algorithm (based on factors associated with treatment response), when compared with a standard clinical assessment, more clinically and cost effective?

    Recommendation ID CG123/5 Question Use of a simple algorithm compared with a standard clinical assessment:- For people with a common mental

    Research recommendation
    Published
    9 June 2015

  12. Use of biomarkers to diagnose and initiate treatment:- What is the clinical and cost effectiveness of procalcitonin (PCT) point-of-care tests at initial triage for diagnosis of serious infection and the initiation of appropriate antibiotic therapy?

    Recommendation ID NG51/3 Question Use of biomarkers to diagnose and initiate treatment:- What is the clinical and cost effectiveness of

    Research recommendation
    Published
    25 August 2016

  13. Use of low-molecular-weight heparin to treat patients with an acute painful sickle cell episode:- Are therapeutic doses of low-molecular-weight heparin (LMWH) effective, compared with prophylactic doses of LMWH, in reducing the length of stay in hospital of patients with an acute painful sickle cell episode?

    Recommendation ID CG143/2 Question Use of low-molecular-weight heparin to treat patients with an acute painful sickle cell episode:- Are

    Research recommendation
    Published
    9 June 2015

  14. Use of technology in providing care- What are the views and experiences of people who use adult social care services on assistive technologies?

    Recommendation ID NG86/4 Question Use of technology in providing care- What are the views and experiences of people who use adult social

    Research recommendation
    Published
    14 November 2018

  15. What is the clinical and cost effectiveness of using different thresholds of LDL‑C concentration in primary care case finding?

    Recommendation ID CG71/1 Question What is the clinical and cost effectiveness of using different thresholds of LDL‑C concentration in primary

    Research recommendation
    Published
    15 November 2019